<DOC>
	<DOCNO>NCT01272856</DOCNO>
	<brief_summary>The purpose study test safety study drug abatacept see effect ( good bad ) patient relapse polychondritis .</brief_summary>
	<brief_title>Study Safety Abatacept Relapsing Polychondritis</brief_title>
	<detailed_description>After screen period 4 week , patient fulfill inclusion exclusion criterion receive open-label subcutaneous abatacept consist 125 mg weekly , begin 1 week thru Week 24 . Throughout study , blood collect clinical laboratory safety , pharmacodynamics biomarkers . Disease activity assessment include laboratory evaluation acute phase reactant , pulmonary function testing , compute tomography neck chest , electrocardiogram , echocardiogram , audiogram , physician assessment chondritis activity , swell tender joint count , patient- physican-reported outcome . Adverse event concomitant medication record .</detailed_description>
	<mesh_term>Polychondritis , Relapsing</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>1 . Signed Written Informed Consent 2 . Diagnosed relapse consist 2 major 1 major + 2 minor criterion follow : Major criterion 1 . Proven inflammatory episode involve auricular cartilage 2 . Proven inflammatory episode involve nasal cartilage 3 . Proven inflammatory episode involve laryngotracheal cartilage Minor criterion 1 . Ocular inflammation ( conjunctivitis , keratitis , episcleritis , uveitis ) 2 . Hearing loss 3 . Vestibular dysfunction 4 . Seronegative inflammatory arthritis Active RPC base least one following : Active chondritis define active inflammation , observed Investigator , auricular and/or nasal cartilage Active tracheal and/or pulmonary disease document abnormal spirometry chest compute tomography Erythrocyte sedimentation rate ≥ 30 mm/hr Creactive protein ≥ 0.6 mg/dL If receive follow medication , stable dose duration indicate without intent change throughout study : Azathioprine , methotrexate , mycophenolate , leflunomide : 1 month Corticosteroids : 2 week Nonsteroidal antiinflammatory drug ( NSAIDs ) : 1 week 3 . Age Sex Men woman , great 18 year age Women childbearing potential must use adequate method contraception avoid pregnancy throughout study 10 week last dose study drug minimize risk pregnancy . Women child bear age include woman experience menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal . Postmenopause define : Amenorrhea last great 12 consecutive month without another cause , For woman irregular menstrual period take hormone replacement therapy ( HRT ) , document serum folliclestimulating hormone ( FSH ) level great 35 mIU/mL . Women use oral contraceptive , hormonal contraceptive ( vaginal product , skin patch , implant injectable product ) , mechanical product intrauterine device barrier method ( diaphragm , condom , spermicide ) prevent pregnancy , practice abstinence partner sterile ( eg , vasectomy ) consider childbearing potential . Women child bear age must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 72 hour start investigational product . A male subject father potential must use adequate method contraception avoid conception throughout study 10 week last dose study drug minimize risk pregnancy . 1 . Sex Reproductive Status Women child bear age unwilling unable use acceptable method avoid pregnancy entire study period 10 week last dose study drug . Women pregnant breastfeeding . Women positive pregnancy test enrollment administration abatacept . 2 . Target Disease Exceptions Fulfills American College Rheumatology criterion connective tissue disease , necessarily limited systemic lupus erythematosus , systemic sclerosis ( scleroderma ) , polymyositis dermatomyositis , rheumatoid arthritis , possess another distinct condition know associated chondritis , Wegener 's granulomatosis Behcet 's disease Use cyclophosphamide , cyclosporine A tacrolimus within one month time administration study drug Use biologic treatment within timeframes indicate : AntiCD20 monoclonal antibody immune celldepleting therapy last 6 month without evidence appropriate lineage reconstitution TNF antagonist , IL1R antagonists , costimulation modulators last 3 month Any prior treatment stem cell transplantation myeloablative therapy Concomitant illness disease activity , opinion investigator , likely require significant additional immunosuppressive therapy ( e.g . &gt; 40 mg daily oral prednisone asthma ) course study 3 . Medical History Concurrent Diseases Subjects impair , incapacitate , incapable completing studyrelated assessment . Subjects current symptom severe , progressive , uncontrolled renal , hepatic , hematologic , gastrointestinal , pulmonary , cardiac , neurologic , cerebral disease , whether related RPC , opinion investigator , might place subject unacceptable risk participation study . Female subject breast cancer screen suspicious malignancy possibility malignancy reasonably exclude additional clinical , laboratory , diagnostic evaluation . Subjects history cancer last 5 year , nonmelanoma skin cell cancer cure local resection carcinoma situ . Existing nonmelanoma skin cell cancer remove , lesion site heal , residual cancer rule administration study drug . Subjects currently abuse drug alcohol . Subjects evidence ( assessed investigator ) active latent bacterial viral infection time potential enrollment , include subject evidence human immunodeficiency virus ( HIV ) detect screen . Subjects herpes zoster cytomegalovirus ( CMV ) resolve less 2 month inform consent document sign . Subjects receive live vaccine within 3 month anticipate first dose study medication . Subjects serious bacterial infection within last 3 month , unless treat resolved antibiotic , chronic bacterial infection ( eg , chronic pyelonephritis , osteomyelitis , bronchiectasis ) . Subjects risk tuberculosis ( TB ) . Specifically exclude study subject history active TB within last 3 year , even treat ; history active TB great 3 year ago , unless documentation prior antiTB treatment appropriate duration type ; current clinical , radiographic , laboratory evidence active TB ; latent TB successfully treat ( ≥ 4 week ) . 4 . Physical Laboratory Test Findings Subjects must positive hepatitis B surface antigen . Subjects positive hepatitis C antibody presence hepatitis C virus also show polymerase chain reaction recombinant immunoblot assay . Subjects follow laboratory value Hemoglobin &lt; 8.5 g/dL WBC &lt; 3000/mm3 ( &lt; 3 x 109/L ) Platelets &lt; 100,000/mm3 ( &lt; 3 x 109/L ) Serum creatinine &gt; 2 time ULN Serum ALT AST &gt; 2 time ULN Any laboratory test result , opinion investigator , might place subject unacceptable risk participation study . 5 . Allergies Adverse Drug Reactions Known sensitivity abatacept 6 . Prohibited Treatments and/or Therapies Subjects time receive treatment investigational drug within 28 day ( less 5 terminal halflives elimination ) Day 1 dose . Any concomitant biologic DMARD , anakinra .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>